IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Sales by Geographical Region
For 2008 Novartis re ported solid growth in Eu rope, Latin Amer ica, Ja pan and emerg ing mar kets, with
China and Rus sia both de liv er ing more than 30% growth. In the high-growth mar kets of, Brazil, China,
In dia, Mex ico, Rus sia, South Ko rea and Tur key, sales rose 18% in lo cal cur rency terms to $4.3 bil lion.
Emerg ing mar kets across the world gen er ated net sales growth of 13% in lo cal cur rency terms to $10 bil -
lion, ris ing to rep re sent 24% of net sales in 2008, com pared to 22% in 2007. Over all growth out side the
USA amounted to 14.4% and sales out side the US rep re sented 69% of to tal sales or $28,598 mil lion. In
the USA growth only re turned in the sec ond half of the year re sult ing in a 1.6% drop in sales for the full
year to $12,861 mil lion, com pared to sales from con tin u ing op er a tions of $13,074 mil lion in 2007. The
USA rep re sented 31% of to tal sales in 2008, down from 34% in 2007. Af ter the USA, the com pany’s larg -
est sin gle mar ket in 2008 was Ger many (10% of sales) with sales of $4,114 mil lion, up 7.1% based on
con tin u ing op er a tions of $3,840 mil lion, fol lowed by Ja pan (7% of sales) with sales of $2,987 mil lion, up
16.7% from $2,559 mil lion. France, which rep re sented 6% of sales in 2008, had sales of $2,284 million,
up 9.8% on 2007.
In Pharmaceuticals sales in the USA fell 1.5% in 2008 to $8,616 mil lion from $8,748 mil lion in 2007,
whereas in the rest of the world sales rose 16% to $17,715 mil lion from $15,277 mil lion in 2007. Ac cord -
ing to Novartis in lo cal cur rency terms sales grew 10% in Eu rope ($10.1 bil lion), 8% in Latin Amer ica
($1.7 bil lion), 4% in Ja pan ($2.6 bil lion), and the rest of the world ($2.6 bil lion) was up 15%. The emerg -
ing mar kets of China, Rus sia, South Ko rea and Tur key de liv ered more than 20% growth in lo cal cur rency
terms, noted Novartis.
One ex cep tion to the poor per for mance in the USA was in Vac cines and Di ag nos tics with sales up 27% to
$765 mil lion from $602 mil lion in 2007. In the rest of the world sales rose 16.9% (12% in lo cal cur rency
terms) to $994 mil lion from $850 million.
For Sandoz sales fell 9.9% in 2008 in the USA to $1,766 mil lion, but rose 11.2% (5% in lo cal cur rency
terms) in the rest of the world to $5,791 mil lion.
Sales in Con sumer Health fell 2.9% in the USA in 2008 to $1,714 mil lion, but rose 11.9% (7% in lo cal cur -
rency terms) in the rest of the world to $4,098 mil lion.
$ millions
16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
0
Sales by Geographic Region
2004 2005 2006 2007 2008
Source: Novartis January 2009/Novartis Annual Reports
Switzerland USA Germany Japan France UK Austria
© 2009 IMS Health In cor po rated or its af fil i ates Page 19